PDS Biotechnology (PDSB) Intangibles (2019 - 2020)
PDS Biotechnology's (PDSB) quarterly Intangibles came in at $3.0 million in Q4 2020, little changed YoY from $3.0 million in Q1 2020, and little changed on a QoQ basis from $3.0 million in Q3 2020.
PDS Biotechnology (PDSB) Intangibles (2019 - 2020) Analysis & Trends
PDS Biotechnology (PDSB) has 2 years of Intangibles data on file, last reported at $3.0 million in Q4 2020.
- Quarterly Intangibles changed 0.0% year-over-year to $3.0 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $3.0 million (changed 0.0% YoY) and the FY2020 annual result came in at $3.0 million, changed 0.0% from the prior year.
- Intangibles was little changed at $3.0 million in Q4 2020, from $3.0 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $3.0 million in Q4 2019 to a low of $1.2 million in Q1 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 266.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 60.96 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 93.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PDS Biotechnology | 12.02 Mn | 12.02 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 2.97 Mn |
| Sep 30, 2020 | 2.97 Mn |
| Jun 30, 2020 | 2.97 Mn |
| Mar 31, 2020 | 2.97 Mn |
| Dec 31, 2019 | 2.97 Mn |
| Sep 30, 2019 | 1.22 Mn |
| Jun 30, 2019 | 1.22 Mn |
| Mar 31, 2019 | 1.22 Mn |